Payal Kohli, MD, FACC

Articles by Payal Kohli, MD, FACC

Addressing Fenofibrates’ Lack of Cardiovascular Benefit, With Payal Kohli, MD, FACC

January 6th 2026

Kohli discusses the importance of the FDA’s recent label change and how clinicians can help reduce the continued prescription of ineffective medication.

Patient Case No. 2

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

January 8th 2025

Panelists discuss how chronic kidney disease (CKD) and uncontrolled hypertension create a damaging cycle, in which hypertension accelerates kidney damage while declining kidney function makes blood pressure harder to control.

Patient Case No. 1

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

January 1st 2025

Panelists discuss how evaluating uncontrolled hypertension in patients with early kidney dysfunction requires a careful investigation of underlying causes, including medication adherence, lifestyle factors, and potential secondary hypertension.

Tips for Precise Readings

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

January 1st 2025

Panelists discuss how proper blood pressure measurement techniques require careful attention to patient positioning, cuff size selection, and standardized procedures to ensure accurate readings.

Hypertension in Pregnancy and Women

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

December 25th 2024

A panelist discusses how hypertensive disorders during pregnancy remain a leading cause of maternal mortality worldwide, affecting 5-10% of pregnancies and requiring careful monitoring, early detection, and appropriate medical management to protect both mother and baby.

PRECISION trial

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

December 25th 2024

Panelists discuss how the PRECISION trial evaluated aprocitentan, a dual endothelin receptor antagonist (ERA), in patients with resistant hypertension taking 3 antihypertensive medications including a diuretic.

Endothelin Pathway

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

December 18th 2024

Panelists discuss how the endothelin pathway critically regulates blood pressure and vascular health through the interplay between vasodilators and vasoconstrictors such as endothelin-1, representing a key mechanism in hypertension pathophysiology.

Current Therapeutic Guidelines for Managing Resistant Hypertension

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

December 18th 2024

Panelists discuss how resistant hypertension management requires a structured approach combining lifestyle modifications, optimal doses of multiple drug classes, and the identification of underlying causes such as sleep apnea.

Difficult-to-Treat Hypertension Treatment Strategies

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

December 11th 2024

Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.

Drug Classes Available to Treat Patients With High Blood Pressure

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

December 11th 2024

Current Limitations With Traditional Antihypertensive Drugs

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

December 4th 2024

Panelists discuss how traditional antihypertensive medications face challenges including adverse reactions, complex dosing regimens, and variable efficacy across different patient populations, which can limit their therapeutic success.

Unmet Needs in HTN: Patient Adherence, Comorbid Conditions, and Prevalence

ByManesh R. Patel, MD,Payal Kohli, MD, FACC,John M. Flack, MD, MPH, FASH,C. Michael Gibson, MD, MS

December 4th 2024

Panelists discuss how poor medication adherence and comorbidities such as chronic kidney disease (CKD) contribute to uncontrolled hypertension despite the availability of numerous treatment options, highlighting key challenges in achieving effective blood pressure management.

Looking Into the Future of Lipid Management

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

January 11th 2024

Dr Taub, Dr Patel, and Dr Kohli look ahead to the future of the management of cardiovascular risk and hyperlipidemia

How to Select Between Available LDL-C Lowering Therapies

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

January 11th 2024

Cardiologists discuss how to select the right treatment for your patient with hyperlipidemia

Clinical Trial Results on Novel Nonstatins Agents.

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

January 11th 2024

Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.

Mechanism of Action of Nonstatin Therapies

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

January 4th 2024

Dr Kohli gives an overview of the mechanisms of action of non-statin agents for the management of hyperlipidemia.

The Cumulative Burden of LDL-C

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

January 4th 2024

Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.

Overcoming Access Barriers to Novel Non Statin Therapies

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh Patel, MD,Pam Taub, MD, FACC, FASPC

December 21st 2023

Dr Taub describes effective strategies in overcoming access barriers to novel lipid lowering therapies.

Combination Therapy in LDL Lowering

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

December 21st 2023

Expert cardiologists describe the importance of combination therapy for hyperlipidemia in high risk patients

Nonstatin Agents for LDL-C Lowering

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

December 14th 2023

Dr Taub and Dr Patel discuss which non statin agents are available for LDL-C lowering.

How Low is Too Low in LDL-C?

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

December 14th 2023

Expert cardiologists discuss if there is such a thing as an LDL that is a too low.

Matching the Intensity of Treatment to Cardiovascular Risk

ByC. Michael Gibson, MD,Manesh R. Patel, MD,Payal Kohli, MD, FACC,Pam Taub, MD, FACC, FASPC

December 7th 2023

Dr Taub discusses how to match the intensity of lipid lowering therapy to the assessed cardiovascular risk.

Assessing Cardiovascular Risk in Your Patients

ByC. Michael Gibson, MD,Payal Kohli, MD, FACC,Manesh R. Patel, MD,Pam Taub, MD, FACC, FASPC

December 7th 2023

Dr Taub and Dr Patel discuss how to assess for cardiovascular risk in your patients.

Clinical Pearls on Lipid Management

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.

Novel Targets for Lipid Level Lowering and Implementation of Lipid Therapy

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.

The Role of Lipoprotein A in Lipid Lowering

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.

Long-term efficacy and safety of PCSK9 inhibitors

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.

Starting Combination Therapy Early

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

October 5th 2023

The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.

Nonstatin Lipid-Lowering Agents

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

October 5th 2023

Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.

Statin Intolerance

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 28th 2023

Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.